Endothelial-to-mesenchymal transition (EndMT) has been shown to contribute to organ fibrogenesis, and we have reported that the anti-EndMT effect of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) is associated with restoring expression of diabetessuppressed fibroblast growth factor receptor (FGFR), the key anti-EndMT molecule. FGFR1 is the key inhibitor of EndMT via the suppression of the transforming growth factor β (TGFβ) signaling pathway, and mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) inhibits integrin β1, a key factor in activating TGFβ signaling and EndMT. Here, we showed that the close proximity between AcSDKP and FGFR1 was essential for the suppression of TGFβ/smad signaling and EndMT associated with MAP4K4 phosphorylation (P-MAP4K4) in endothelial cells. In cultured human dermal microvascular endothelial cells (HMVECs), the anti-EndMT and anti-TGFβ/smad effects of AcSDKP were lost following treatment with a neutralizing FGFR1 antibody (N-FGFR1) or transfection of FRS2 siRNA. The physical interaction between FGFR1 and P-MAP4K4 in HMVECs was confirmed by proximity ligation analysis and an immunoprecipitation assay. AcSDKP induced P-MAP4K4 in HMVECs, which was significantly inhibited by treatment with either N-FGFR1 or FRS2 siRNA. Furthermore, MAP4K4 knockdown using specific siRNAs induced smad3 phosphorylation and EndMT in HMVECs, which was not suppressed by AcSDKP. Streptozotocin-induced diabetic CD-1 mice exhibited suppression of both FGFR1 and P-MAP4K4 expression levels associated with the induction of TGFβ/smad3 signaling and EndMT in their hearts and kidneys; those were restored by AcSDKP treatment. These data demonstrate that the AcSDKP-FGFR1-MAP4K4 axis has an important role in combating EndMT-associated fibrotic disorders.
and decreased expression of endothelial cell markers, such as VE-cadherin and CD31 (also known as platelet endothelial cell adhesion molecule-1). 11, 12 Accumulating evidence demonstrates that transforming growth factor β (TGFβ)/smad signaling is a major inducer of EndMT, and proteins in the non-TGFβ pathway, such as β-catenin and Notch, are also involved in EndMT induction. 13, 14 N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) is a tetrapeptide that is enzymatically cleaved by prolyl oligopeptidase (POP) from the N-terminal sequence of thymosinβ4 (Tβ4) and hydrolyzed by angiotensin-converting enzyme. 15, 16 Furthermore, AcSDKP has been proven to have an antifibrotic effect in various organ fibrosis models. [17] [18] [19] [20] Long-term treatment with AcSDKP suppresses renal fibrosis by inhibiting the TGFβ/smad signaling pathway. 21 In the kidneys of diabetic mice, the decreased fibroblast growth factor receptor (FGFR) level was restored by AcSDKP treatment, 22 and fibroblast growth factors (FGFs) have a key role in the normal state of vascularity. 23, 24 FGF2/FGFR1 signaling is associated with the induction of the miRNA let-7, ameliorating the vascular disease state through the suppression of TGFβ/TGFβR1-induced EndMT. 25 Furthermore, FGFR1 is a key inhibitor of TGFβ/smad signaling in endothelial cells. 26 However, the molecular interplay between AcSDKP and FGFR1 signaling in endothelial cells is still unclear.
Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) belongs to the Ste20 family of kinases, which have been shown to affect various biological processes, such as embryonic development and inflammation. MAP4K4 is associated with multiple molecular pathways, including integrin signaling and the mammalian target of rapamycin (mTOR). 27 In endothelial cells, MAP4K4 inhibits integrin β1 activity by inducing moesin. 28 Furthermore, integrin β1 induces the epithelial-mesenchymal transition (EMT) and organ fibrosis via the activation of TGFβ/smad signaling. [29] [30] [31] We have shown that the interaction between dipeptidyl peptidase 4 (DPP-4) and integrin β1 induces EndMT by activating TGFβ/smad signaling. 32 TGFβ/smad signaling is also inhibited by Misshapen (msn) kinases (the mammalian orthologs of MAP4K4). 33 Here, we hypothesize that the AcSDKP-FGFR1-MAP4K4 axis has a key role in the suppression of TGFβ/smad signaling and EndMT in endothelial cells.
Results
The proximity of AcSDKP and FGFR1 is essential for AcSDKP-mediated inhibition of TGFβ/smad signaling pathway in endothelial cells. A duolink in situ proximity ligation assay (PLA) was performed to analyze the proximity between AcSDKP and FGFR1 in cultured human dermal microvascular endothelial cell (HMVEC) (Figure 1a ). AcSDKP and FGFR1 displayed close proximity in normal cultured HMVECs (Figure 1a) , suggesting that endogenous AcSDKP interacts with FGFR1. Exogenous AcSDKP incubation in endothelial cells further increased the close proximity between AcSDKP and FGFR1 ( Figure 1a ). In addition, in the presence of a neutralizing FGFR1 antibody (N-FGFR1), which suppresses FGFR1 activity in endothelial cells, the close proximity between AcSDKP and FGFR1 was markedly diminished in HMVECs, even with AcSDKP incubation (Figure 1a) . We previously reported that the anti-TGFβ1/ smad and anti-kidney fibrosis effects of AcSDKP were associated with the restoration of FGFR phosphorylation (P-FGFR) and FGFR levels. 22, 34 We also confirmed that AcSDKP significantly inhibited TGFβ2-induced smad3 phosphorylation (p-smad3), p-smad2, TGFβR1 and TGFβR2 levels, and restored TGFβ2-suppressed FGFR1 in endothelial cells (Figures 1b and c and Supplementary Figure S1a) . Interferon-γ (IFN-γ) has been confirmed to inhibit FGFR1 protein levels, 25 and treatment of HMVECs with AcSDKP was associated with increased FGFR1/P-FGFR1 levels and decreased expression of IFN-γ (Supplementary Figure S1b) . Furthermore, Tβ4 restored TGFβ2-suppressed FGFR1 levels, and a POP inhibitor (KYP-2047) abolished the effect of Tβ4 (Supplementary Figure S2a) . The bone Figure 1 Proximity between AcSDKP and FGFR1 inhibits the TGFβ/smad signaling pathway in HMVECs. (a) HMVECs were treated with N-FGFR1 (1.5 μg/ml) for 48 h with or without preincubation with AcSDKP (100 nM) for 2 h, and the proximity between AcSDKP and FGFR1 was analyzed by the Duolink In Situ Assay. For each slide, images at a × 400 original magnification were obtained from six different areas. (b and c) HMVECs were treated with TGFβ2 (5 ng/ml) for 15 min or 48 h with or without preincubation with AcSDKP for 2 h, and the p-smad3, TGFβR1, TGFβR2 and FGFR1 levels were analyzed by western blot. Densitometric analysis of the p-smad3/smad3, TGFβR1/β-actin, TGFβR2/β-actin and FGFR1/β-actin levels from each group (n = 6) were analyzed. (d and e) HMVECs were incubated with TGFβ2 for 15 min or 48 h with or without preincubation with AcSDKP or its mutants (AcDSPK, AcSDKA, AcADKP) (100 nM) for 2 h. The p-smad3/smad3, TGFβR1/β-actin, TGFβR2/β-actin and FGFR1/β-actin protein levels were analyzed by western blot morphogenetic protein (BMP) pathway has been associated with EndMT induction. 35 We investigated whether AcSDKP inhibits EndMT by suppressing the BMP pathway, and AcSDKP did not inhibit the BMP-2/BMP-4-induced expression of p-smad1/5/8 in endothelial cells (Supplementary Figure S2b) . To further elucidate the significance of AcSDKP on FGFR1 levels and its functional relevance, three AcSDKP mutant peptides, AcSDKA, AcDSPK and AcADKP, were constructed. Western blot analysis revealed that the AcSDKP mutants had no effect on the levels of TGFβ2-induced p-smad3, TGFβR1 and TGFβR2 and suppressed FGFR1 in endothelial cells (Figures 1d and e) .
AcSDKP suppresses TGFβ/smad signaling and EndMT through the FGFR1 pathway. N-FGFR1 suppressed FGFR1 and induced both TGFβR1 and TGFβR2 in cultured endothelial cells (Figure 2a) . Treating the cultured cells with N-FGFR1 increased the p-smad3 and TGFβR1 protein levels, especially when N-FGFR1 and TGFβ2 were incubated together (Figure 2b ). However, in the presence of N-FGFR1, increased p-smad3 and TGFβR1 levels were not suppressed by AcSDKP in endothelial cells (Figure 2b ), suggesting that AcSDKP-suppressed TGFβ/smad signaling is dependent on the FGFR1 pathway. Nevertheless, AcSDKP did not bind TGFβR1 or TGFβR2 in endothelial cells (Supplementary Figure S3) , likely indicating that there is no distinct interaction between AcSDKP and TGFβRs. FGF2/FGFR1 has been shown to inhibit EndMT induction. 25, 26 N-FGFR1 treatment in endothelial cells induced EndMT, as revealed by the decreased CD31 levels and the increased SM22α, FSP1 and α-SMA, and was associated with TGFβR1 and TGFβR2 levels, especially when N-FGFR1 and TGFβ2 were applied together ( Figure 2c and Supplementary Figures S4a and b) . In addition, the N-FGFR1-induced EndMT was not reversed FGF2/FGFR1 regulates MAP4K4 signaling in endothelial cells. We next investigated the mechanism responsible for decreasing the expression of phosphorylated MAP4K4 (P-MAP4K4) after the FGFR1 pathway was shut down. Immunofluorescence staining revealed that the siRNAmediated knockdown of FRS2 in endothelial cells significantly reduced the expression of P-MAP4K4 compared with that of the control group (Figure 3a) , and TGFβ2-treated cells also showed a similar result (Figure 3a ). Western blot analysis was performed to confirm these findings; the expression of P-MAP4K4 in endothelial cells was suppressed by N-FGFR1 and activated by FGF2 (Figures 3b and c) . The close proximity between FGFR1 and P-MAP4K4 was observed in normal cultured endothelial cells (Figure 4a MAP4K4 signaling is activated by AcSDKP in a FGFR1/ FRS2-dependent manner. We next examined whether AcSDKP-activated MAP4K4 signaling in endothelial cells via the FGFR1/FRS2 pathway. Endothelial cells were treated with either N-FGFR1 or FRS2 siRNA in the presence or absence of FGF2 or AcSDKP. In the presence of N-FGFR1, the P-MAP4K4 levels were significantly decreased in endothelial cells and could not be restored by FGF2 (Figure 5a ). Similarly, AcSDKP also failed to restore the N-FGFR1-suppressed P-MAP4K4 levels (Figure 5b ). Furthermore, in FRS2 siRNA-treated endothelial cells, neither AcSDKP nor FGF2 restored FRS2 siRNA-suppressed P-MAP4K4 levels (Figures 5c and d) . These findings suggest that FGFR1 is a key upstream molecule of MAP4K4 signaling in endothelial cells.
MAP4K4 is a key inhibitor of TGFβ/smad signaling and EndMT via suppression of integrin β1 signaling. In endothelial cells, the increased p-smad3 level induced by MAP4K4 siRNA was not suppressed by AcSDKP treatment (Figure 6a ). In addition, MAP4K4 siRNA treatment led to decreased expression of the endothelial cell markers VE-cadherin and CD31 and increased expression of the mesenchymal markers FSP1, SM22α and vimentin (Figure 6b ), suggesting that MAP4K4 deficiency induces EndMT. However, AcSDKP did not inhibit the MAP4K4 siRNA-induced EndMT (Figure 6b ). MAP4K4 has been shown to inhibit the expression of integrin β1 in endothelial cells, 28 and we have previously reported that the interaction between DPP-4 and integrin β1 can induce EndMT. 32 In this study, both TGFβ2 and MAP4K4 siRNA increased the expression of integrin β1 in endothelial cells, especially when TGFβ2 and MAP4K4 siRNA were applied together Figure S7) . Therefore, to investigate the role of the AcSDKP-FGFR1-MAP4K4 signaling pathway in EndMT induction in vivo, we developed AcSDKP-treated streptozotocin (STZ)-induced diabetic mice. FGFR1 and P-MAP4K4 expression in their cardiac tissue endothelial cells was analyzed by immunofluorescence, and FGFR1 and P-MAP4K4 expression was markedly suppressed in the diabetic hearts compared with the control group (Figure 7a ). In addition, AcSDKP treatment restored the diabetessuppressed endothelial FGFR1 and P-MAP4K4 expression (Figure 7a ). We next analyzed endothelial cells in hearts undergoing EndMT, which were recognized by double labeling with CD31/α-SMA or VE-cadherin/SM22α antibodies. The diabetic hearts exhibited more endothelial cells undergoing EndMT compared with the control hearts (Figure 7b) , and AcSDKP treatment restored the diabetes-induced EndMT (Figure 7b ). When compared with the control mice, the diabetic mice exhibited increased endothelial p-smad3 levels in the hearts, which was inhibited by AcSDKP (Figure 7c ). In the hearts, AcSDKP reversed the diabetessuppressed FGFR1 and P-MAP4K4 levels and the diabetesinduced TGFβ2 levels (Figure 7d) . However, the TGFβ1 and TGFβ3 protein levels were not significantly altered (Figure 7d ). In kidneys, AcSDKP also restored the diabetessuppressed FGFR1 and P-MAP4K4 levels and the diabetesinduced TGFβ1 and TGFβ2 expression (Supplementary Figure S6) . The TGFβ3 protein level was not significantly altered (Supplementary Figure S6) .
Discussion
In our study, we found that AcSDKP inhibited TGFβ/smad signaling and EndMT in endothelial cells via the FGFR1/ Figure 4 The proximity between FGFR1 and P-MAP4K4 decreases in FGFR1-deficient cells. (a) HMVECs were treated with N-FGFR1 or TGFβ2 for 48 h. The proximity between FGFR1 and P-MAP4K4 was analyzed using the Duolink In Situ Assay. For each slide, images at × 400 original magnification were obtained from six different areas. (b) immunoprecipitation analysis with either a P-MAP4K4 or a FGFR1 antibody was performed and analyzed by western blot. Then, the FGFR1 and P-MAP4K4 levels with N-FGFR1 or TGFβ2 treatment were analyzed by western blot in endothelial cells
The anti-EndMT effect of AcSDKP via FGFR1 J Li et al MAP4K4 pathway in vitro and in vivo. In vitro, TGFβ/smad signaling and the associated EndMT were induced by FGFR1 deficiency in a TGFβ2-dependent manner. AcSDKP-activated MAP4K4 signaling through the FGFR1/FRS2 pathway. AcSDKP could not suppress the TGFβ/smad signaling and EndMT induced by MAP4K4 deficiency. In vivo, we also confirmed that AcSDKP restored the expression of FGFR1 and P-MAP4K4 and was associated with TGFβ/smad3 expression and EndMT in diabetic hearts and kidneys. AcSDKP exhibits anti-EndMT and antifibrotic effects in several organ fibrosis models, 22, 37 and EndMT has shown to be induced by TGFβ2 in both a smad-dependent and a smadindependent manner. 11, 13, 38 AcSDKP has also been shown to inhibit TGFβ1-induced p-smad2/3. 34 However, the detailed molecular mechanisms by which AcSDKP inhibits TGFβ/ smad signaling and EndMT in endothelial cells are not entirely clear. A recent study confirmed that FGF/FGFR suppressed TGFβ-induced EndMT via the induction of miR-let-7s. 25 Our previous study also demonstrated that AcSDKP restored diabetes-suppressed FGFR and FGFR phosphorylation levels. 22 FGFR1 has been confirmed as a key inhibitor of TGFβ-induced EndMT. 26 Here, we established the FGFR1 signaling-dependent inhibitory effects of AcSDKP on TGFβ/ smad signaling and EndMT in HMVECs (Figure 8 ). AcSDKP The anti-TGFβ/smad and anti-EndMT effects of AcSDKP were lost when FGFR1 signaling was disrupted. FGFR1 has a key role in the regulation of cell migration, [39] [40] [41] and the interaction between FGFR1 and integrin β1 is essential for endothelial cell migration. 42 In addition, MAP4K4 promotes endothelial cell migration via inactivation of integrin β1 signaling. 28 Here, we confirmed that FGFR1 was essential for regulation of the MAP4K4 pathway in endothelial cells, as suppression of FGFR1 clearly decreased P-MAP4K4 levels. Conversely, FGF2-induced FGFR1 activation was associated with the induction of P-MAP4K4 (Figure 8) .
Kaneko et al. 33 reported that misshapen, the mammalian ortholog of MAP4K4, was a direct suppressor of the TGFβ/smad pathway. Recent studies showed that MAP4K4 deficiency in T cells led to insulin resistance and that MAP4K4 expression was significantly suppressed in type 2 diabetic mice. 43, 44 Despite these important biological roles, little information is known regarding the regulation of MAP4K4 in TGFβ/smad signaling and EndMT induction. Our data demonstrated that AcSDKPactivated P-MAP4K4 expression was dependent on the FGFR1 signaling pathway. In addition, the suppression of MAP4K4 in endothelial cells significantly induced TGFβ/smad signaling and EndMT, even in the presence of AcSDKP (Figure 8) . In vivo, we demonstrated that AcSDKP reversed the diabetes-suppressed FGFR1 and P-MAP4K4 levels associated with the induction of TGFβ/ smad signaling and EndMT in endothelial cells in hearts and kidneys. MAP4K4 has been shown to suppress integrin β1 signaling in endothelial cells 28 and integrin β1 is associated with TGFβ signaling and EndMT induction in endothelial cells. 32, 45 In our study, suppression of MAP4K4 increased the integrin β1 levels in endothelial cells, and AcSDKP had no effect on its levels in MAP4K4-deficient cells (Figure 8 ). These data confirmed that MAP4K4 is a key downstream molecule for the anti-EndMT effect of AcSDKP.
Our results confirmed the functional interactions among AcSDKP, FGFR1 and MAP4K4 in endothelial cells. The close proximity between AcSDKP and FGFR1 inhibited the EndMT associated with TGFβ/smad signaling by activating the MAP4K4 pathway. In addition, AcSDKP restored both diabetes-suppressed FGFR1 and P-MAP4K4 levels and induced TGFβ/smad signaling and EndMT in heart and kidney. These findings reveal an AcSDKP-FGFR1-MAP4K4 signaling axis, offering new insights into endothelial cell biology and a potential target for future studies of EndMTassociated organ fibrosis.
Materials and Methods
Reagents. The AcSDKP peptide was a gift from Asabio Bio Technology (Osaka, Japan). The AcSDKA (100 nmol, SQ14640), AcDSPK (100 nmol, SQ14641) and AcADKP (100 nmol, SQ14639) peptides were purchased from Scrum Inc. (Tokyo, Japan). The following antibodies were purchased from Abcam (Cambridge, UK): mouse monoclonal anti-FGFR1 (1 : 500, ab823), rabbit polyclonal anti-integrin β1 (1 : 500, ab115146), mouse monoclonal anti-vimentin (1 : 2000, ab8978), rabbit polyclonal anti-α-SMA (1 : 1000, ab5694), rabbit monoclonal anti-IFN-γ (1 : 1000, ab133566), rabbit polyclonal anti-TGFβRII (1 : 1000, ab61213) and rabbit polyclonal anti-TGFβ3 (1 : 500, ab 15537). The human BMP-4 peptide (1 μg/ml, ab40140) and the human Tβ4 peptide (1 μg/ml, ab42293) were also purchased from Abcam. The mouse monoclonal anti-human CD31 (1 : 1000, AF3628), human neutralizing FGFR1 (1 : 500, MAB765) and neutralizing TGFβ (1-2-3) (1 : 500, MAB1835) antibodies were purchased from R&D Systems (Minneapolis, MN, USA). A rabbit polyclonal anti-phospho-smad3 (s423 and s425) (1 : 1000, 600-401-919) antibody was purchased from Rockland Immunochemicals (Gilbertsville, PA, USA). The mouse monoclonal anti-β-actin (1:10 000, A2228), rabbit anti-TGFβ1 (1:500, SAB4502954) and rabbit anti-TGFβRI (1:500, SAB4502958) antibodies, as well as FGF2 human recombinant (50 μg/ml, SRP4037), KYP-2047 (1 μg/ml, SML0208) and PF-06260933 (1 μmol, PZ-0272) were obtained from Sigma (St. Louis, MO, USA). The rabbit polyclonal anti-phospho-HGK/MAP4K4 PSer801 antibody (1:500, PA5-12874) and the rabbit anti-SMAD2 (1 : 500, #51-1300) antibody were purchased from Thermo Fisher Scientific (Waltham, MA, USA). The rabbit polyclonal anti-HGK/MAP4K4 (1 : 500, NBP1-58853), rabbit polyclonal anti-SM22α (1:1000, NBP1-33003) and rabbit monoclonal anti-VE-cadherin (1:1000, NBP1-43347) antibodies, along with the recombinant human BMP-2 protein (1 μg/ml, NBP1-98923) were obtained from Novus Biologicals (Littleton, CO, USA). The rabbit polyclonal anti-S100A4 (also known as FSP1) (1:200, PRB-497P), rabbit polyclonal anti-FRS2 (1:1000, sc-8318) and goat polyclonal anti-p-smad1/5/8 (1 : 1000, sc-12353) antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). The rabbit polyclonal anti-AcSDKP (1 : 1000, A03881) antibody was purchased from Biocompare (South, San Francisco, CA, USA). The rabbit polyclonal anti-smad3 (1:1000, #9513), rabbit polyclonal anti-p-smad2 (1:400, #3108S) and rabbit anti-phospho-FGFR1 (1:500, #3471) antibodies were obtained from Cell Signaling Technology (Danvers, MA, USA). The TGFβ2 antibody (1:1000, GTX15539) was purchased from Gene Tex (Alton Pkwy, Irvine, CA, USA).
Cell culture and treatment. The HMVECs were cultured in EBM-2 medium supplemented with EGM-2 (5.5 mmol/l glucose, fetal bovine serum, hydrocortisone, hFGF-β, VEGF, R-IGF-1, ascorbic acid, hEGF, GA-1000 and heparin) (Lonza, Alpharetta, GA, USA). When the cells reached 70-80% confluence, TGFβ2 (5 ng/ml), N-FGFR1 (1.5 μg/ml) and TGFβ2 with either the N-FGFR1 or the neutralizing TGFβ (1, 2, 3) antibody (1.0 μg/ml) was added to the experimental medium (a mixture of HuMedia-MVG in serum-free RPMI 1640 medium at a 1 : 3 ratio) with or without preincubation with 100 nM AcSDKP for 2 h.
Transfection experiments. HMVECs were transfected with siRNA (100 nmol/ l) targeting FRS2 (Invitrogen, Carlsbad, CA, USA) or MAP4K4 (Dharmacon, Lafayette, CO, USA) (FRS2: 5′-GCGGAAAAACCGCAAGUTT-3′ and MAP4K4: 5′-GACCAAC UCUGGCUUGUUA-3′). The transfection reagent lipofectamine 2000 (Invitrogen) was used according to the manufacturer's instructions. Cells were incubated with lipofectamine 2000 and target RNA in serum-free medium for 6 h. After this, the medium was replaced by experimental medium (a mixture of serum-free Humedia-EB2 in serum-free RPMI at a 1:3 ratio), the cells were treated as follows: for FRS2 siRNA transfection, the cells were treated with or without FGF2 (50 ng/ml) for 24 h or AcSDKP for 48 h; for the MAP4K4 siRNA transfection, the cells were treated with TGFβ2 for 48 h in the presence or absence of AcSDKP.
Duolink in situ assay. The duolink in situ PLA was performed according to the manufacturer's protocol. Briefly, HMVECs were treated with N-FGFR1 (1.5 ug/ ml) or MAP4K4 siRNA (100 nmol) for 48 h with or without preincubation with AcSDKP. Control IgG was added in the negative control group, and TGFβ2 and control IgG were added in the positive control group. Next, the cells were fixed with 4% paraformaldehyde and permeabilized with 0.2% Triton X-100. After blocking, the cells were incubated overnight with rabbit anti-AcSDKP (1 : 1200) and mouse anti-FGFR1 (1 : 50) or mouse anti-FGFR1 (1 : 50) and rabbit anti-P-MAP4K4 (1 : 1200). The cells were incubated with PLA probe solution for 1 h at 37°C before being treated with a ligase solution for 30 min at 37°C and a polymerase amplification solution for 100 min at 37°C. The samples were immediately mounted with Duolink In Situ Mounting Medium with DAPI for 20 min and analyzed by fluorescence microscopy. For each slide, the images were analyzed from six different view fields at a × 400 magnification.
Western blot analysis. Proteins were harvested using RIPA lysis buffer (lysis buffer, PMSF, protease inhibitor cocktail and sodium orthovanadate, which was purchased from Santa Cruz Biotechnology). The protein lysates were boiled in SDS sample buffer at 100°C for 6 min, separated on SDS-polyacrylamide gels, and then transferred onto PVDF membranes (Pall Corporation, Pensacola, FL, USA) using the semi-dry method. After blocking, the membranes were incubated overnight with primary antibodies at 4°C, followed by the corresponding peroxidase-conjugated secondary antibody for 1 h at room temperature. The blots were developed with an enhanced chemiluminescence detection system (Pierce Biotechnology, Rockford, IL, USA) and visualized using an ImageQuant LAS 400 camera system (GE Healthcare Life Sciences, Uppsala, Sweden). Interacting with co-factor FRS2, FGFR1 recruited MAP4K4 and induced its phosphorylation. Subsequently, p-MAP4K4 suppressed integrinβ1 (integrinβ1 should be localized on the cell surface interacted with some of α integrins). Integrinβ1 was a potent activator of TGF-β signaling and also EndMT. Therefore, AcSDKP could inhibit EndMT through FGFR1-MAP4K4-dependent manner
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Immunoprecipitation. HMVECs were treated with either N-FGFR1 or TGFβ2. After 48 h, the cells were harvested using the RIPA lysis buffer system and centrifuged at 14 000 × g for 15 min at 4°C. The supernatant was then transferred to a new tube, washed twice with protein A solution (Cell Signaling Technology), and incubated with primary antibody overnight at 4°C. Protein A was added again, and incubated for 2 h at 4°C. Next, the solution was centrifuged, and the supernatant was discarded. The pellets were washed three times with RIPA lysis buffer. After the supernatant was discarded, 2 × SDS sample buffer was added to the pellets, and the mixture was boiled for 5 min to elute the captured proteins for western blotting.
Immunofluorescence for cell culture. The treated HMVECs were cultured on eight-well culture slides for 48 h. The cells were then fixed with 100% methanol for 10 min at − 20°C and acetone for 1 min at − 20°C. After blocking with 2% BSA/PBS for 30 min at room temperature, the cells were incubated with primary antibody for 1 h. After being washed with PBS, the slides were incubated with the corresponding secondary antibodies for 30 min. The cells were then extensively washed three times with PBS and mounted with mounting medium containing DAPI (Vector Laboratories, Burlingame, CA, USA). The images were analyzed by fluorescence microscopy (Axio Vert.A1, Carl Zeiss Microscopy GmbH, Jena, Germany).
Immunostaining analysis of mouse tissue. Frozen heart sections were fixed with acetone for 10 min at − 20°C. The sections were blocked with 2% BSA/ PBS for 30 min at room temperature and incubated with primary antibodies against CD31/FGFR1, CD31/P-MAP4K4, CD31/α-SMA, VE-cadherin/SM22α and CD31/psmad3 for 1 h. The sections were then incubated with the corresponding secondary antibodies for 30 min at room temperature and mounted in mounting medium containing DAPI. The images were analyzed by fluorescence microscopy (Axio Vert. A1, Carl Zeiss Microscopy GmbH).
Animal experiments. Control, STZ-treated CD-1 and AcSDKP-treated STZ mice were prepared based on our previous report. 22 Briefly, 8-week-old CD-1 mice were injected with STZ (200 mg/kg). Sixteen weeks after the induction of diabetes, the diabetic mice were divided into two groups, a nontreatment group and an AcSDKP treatment group (500 μg/kg BW/day using an osmotic mini-pump for 8 weeks). The experiments described in the methods were carried out in accordance with the animal protocols of Kanazawa Medical University (protocol numbers 2014-89, 2013-114 and 2014-101).
Statistical analysis. The data are expressed as the mean ± S.E.M. One-way ANOVA followed by the Tukey's multiple comparison test (statistical significance was defined as Po0.05) was used for statistical analysis using GraphPad Prism software (Ver 5.0f, La Jolla, Canada).
